Chronic Hepatitis (CHC), Viral Polymerase Nucleotide Inhibitor & Process Patents Review and Evaluation, Preparation of Sofosbuvir

Volume 3 - Issue 5

Krishnasarma Pathy*

Received: September 26, 2019;   Published: October 09, 2019

DOI: 10.32474/LOJMS.2019.03.000172

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Sofosbuvir is a viral polymerase nucleotide inhibitor that was approved in December 2013 by the United States Food and Drug Administration (FDA), and in January 2014 by the European Medicines Agency for the treatment of HCV infection [1]. The WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection recommend sofosbuvir in combination with ribavirin in genotypes [1-4] HCV infection, either with or without pegylated interferon (depending on the HCV genotype) [5-7]. Sofosbuvir in combination with ribavirin is the first interferon-free HCV treatment (Table 1). The fact that sofosbuvir is all oral simplifies the treatment and will allow expansion in low resource settings with poor health infrastructure.
a. The objective of this paper identify the most relevant process patents with respect to the medicines
b. identify in which countries these patents have been filed and granted
This Article study mainly find numerous patents relating to preparation of Sofosbuvir (Figure 1). These patents will cover different aspects and innovations around the same product. Not all however are equally relevant, as many will cover variations or production processes but would not prevent somebody else to produce the medicine, e.g. by using a different process.

Abstract| Introduction| Discussion| Preparation of Sofosbuvir| Conclusion| References|